ARAY
This is a non-binding development-stage collaboration with no financial terms or product timeline. Monitor for future regulatory filings or product announcements that would indicate commercialization. No near-term revenue or cost impact expected.
Price Chart
Executive Summary
Accuray announced a collaboration with Samsung NeuroLogica to develop advanced volumetric imaging capabilities for the CyberKnife System. The deal is exploratory — no commercial product has been announced, no financial terms were disclosed, and the collaboration is in phased development. This is a non-binding strategic announcement with no immediate revenue or product impact.
Key Facts
- Accuray entered into agreements with Samsung NeuroLogica to pursue volumetric imaging for the CyberKnife System.
- No commercial product has been announced; the collaboration is in phased development.
- No financial terms, milestone payments, or revenue projections were disclosed.
- The announcement was made at the ASTRO Annual Meeting.
- The Royal Marsden NHS Foundation Trust is the first clinical site participating in the collaboration.
Financial Impact
No financial terms disclosed — the collaboration is exploratory with no commercial product announced.
Risk Factors
- No commercial product has been announced — the collaboration may not result in a marketable product.
- Regulatory approvals for any resulting imaging system are uncertain and could delay or prevent commercialization.
- The collaboration is early-stage; Accuray may need to invest additional capital without guaranteed return.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302890828 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | Press Release | $0.1340 | awaiting T+5 | — | $0.1326 (−1.04%) |
Oct 16, 2026 10d ago | DEF 14A | $0.1400 $0.1250 | ▲ +10.71% | ▲ +10.57% | $0.1326 (+5.29%) |
Oct 13, 2026 13d ago | 8-K | $0.1751 $0.1370 | ▼ −21.76% | ▼ −22.21% | $0.1326 (−24.27%) |
Oct 7, 2026 19d ago | 3 | $0.2414 $0.1738 | ▼ −28.00% | ▼ −27.73% | $0.1326 (−45.07%) |
Oct 6, 2026 20d ago | 8-K | $0.2534 $0.1751 | ▲ +30.90% | ▲ +29.92% | $0.1326 (+47.67%) |
Sep 27, 2026 4w ago | Press Release | $0.2998 $0.3017 | ▲ +0.63% | ▼ −0.57% | $0.1326 (−55.77%) |
Sep 22, 2026 4w ago | Institutional Cluster | $0.2300 $0.3000 | ▲ +30.43% | ▲ +31.62% | $0.1326 (−42.35%) |
Sep 14, 2026 6w ago | EFFECT | $0.2453 $0.2400 | ▲ +2.16% | ▲ +2.27% | $0.1326 (+45.94%) |
Sep 11, 2026 6w ago | Press Release | $0.2502 $0.2336 | ▼ −6.63% | ▼ −6.41% | $0.1326 (−47.00%) |
Aug 19, 2026 9w ago | Press Release | $0.2924 $0.2621 | ▲ +10.36% | ▲ +11.48% | $0.1326 (+54.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers